Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Comput Biol Chem. 2018 Jun;74:115-122. doi: 10.1016/j.compbiolchem.2018.02.017. Epub 2018 Mar 8.
Pseudomonas aeruginosa is an opportunistic gram-negative bacterium that has the capability to acquire resistance under hostile conditions and become a threat worldwide. It is involved in nosocomial infections. In the current study, potential novel drug targets against P. aeruginosa have been identified using core proteomic analysis and Protein-Protein Interactions (PPIs) studies. The non-redundant reference proteome of 68 strains having complete genome and latest assembly version of P. aeruginosa were downloaded from ftp NCBI RefSeq server in October 2016. The standalone CD-HIT tool was used to cluster ortholog proteins (having >=80% amino acid identity) present in all strains. The pan-proteome was clustered in 12,380 Clusters of Orthologous Proteins (COPs). By using in-house shell scripts, 3252 common COPs were extracted out and designated as clusters of core proteome. The core proteome of PAO1 strain was selected by fetching PAO1's proteome from common COPs. As a result, 1212 proteins were shortlisted that are non-homologous to the human but essential for the survival of the pathogen. Among these 1212 proteins, 321 proteins are conserved hypothetical proteins. Considering their potential as drug target, those 321 hypothetical proteins were selected and their probable functions were characterized. Based on the druggability criteria, 18 proteins were shortlisted. The interacting partners were identified by investigating the PPIs network using STRING v10 database. Subsequently, 8 proteins were shortlisted as 'hub proteins' and proposed as potential novel drug targets against P. aeruginosa. The study is interesting for the scientific community working to identify novel drug targets against MDR pathogens particularly P. aeruginosa.
铜绿假单胞菌是一种机会性革兰氏阴性菌,能够在恶劣环境下获得耐药性,成为全球威胁。它与医院获得性感染有关。在本研究中,使用核心蛋白质组学分析和蛋白质-蛋白质相互作用(PPIs)研究鉴定了针对铜绿假单胞菌的潜在新型药物靶标。2016 年 10 月,从 ftp NCBI RefSeq 服务器下载了具有完整基因组和最新组装版本的 68 株非冗余参考蛋白质组。使用独立的 CD-HIT 工具对所有菌株中存在的直系同源蛋白(具有>=80%氨基酸同一性)进行聚类。泛蛋白组被聚类为 12380 个同源蛋白簇(COPs)。通过使用内部 shell 脚本,从 3252 个常见 COPs 中提取出 3252 个共同 COPs,并指定为核心蛋白质组簇。通过从常见 COPs 中获取 PAO1 的蛋白质组,选择了 PAO1 菌株的核心蛋白质组。结果,筛选出 1212 种非同源但对病原体生存至关重要的蛋白质。在这 1212 种蛋白质中,有 321 种是保守的假设蛋白质。考虑到它们作为药物靶标的潜力,选择了这 321 种假设蛋白质,并对其可能的功能进行了表征。根据可药性标准,筛选出 18 种蛋白质。通过使用 STRING v10 数据库研究 PPI 网络,确定了相互作用伙伴。随后,从 8 种蛋白质中筛选出 8 种作为“枢纽蛋白”,并提出作为针对铜绿假单胞菌的潜在新型药物靶标。这项研究对于致力于鉴定针对多药耐药病原体特别是铜绿假单胞菌的新型药物靶标的科学界来说是很有趣的。